Aziriv Tablets

Indication

Prevention of venous thromboembolism (VTE) in patients undergoing hip or knee replacement surgery, treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation.

Dosage (summary)

10 mg once daily for VTE prophylaxis after surgery; 15 mg twice daily for the first 21 days, then 20 mg once daily for DVT/PE treatment; 20 mg once daily for stroke prevention in atrial fibrillation.

Onset of Action / Duration

Onset of action is within 2 to 4 hours; duration of action is approximately 24 hours.

Special Populations

• Elderly patients
• Patients with renal impairment
• Patients with hepatic impairment
• Patients with a history of bleeding disorders

Pregnancy & Breastfeeding

Use during pregnancy only if the potential benefit justifies the potential risk to the fetus. Rivaroxaban is excreted in breast milk; caution is advised when administering to nursing mothers.

Key Drug Interactions

• Strong CYP3A4 inhibitors (e.g., ketoconazole, ritonavir) may increase rivaroxaban levels.
• Strong CYP3A4 inducers (e.g., rifampicin, St. John's Wort) may decrease rivaroxaban levels.
• Anticoagulants, antiplatelet agents, and NSAIDs may increase the risk of bleeding.

Contraindications

• Active bleeding
• Severe renal impairment (CrCl < 15 mL/min)
• Severe hepatic impairment
• Hypersensitivity to rivaroxaban or any excipients

Common side effects

• Bleeding complications
• Anemia
• Nausea
• Vomiting
• Liver enzyme elevations

Counselling Points

• Take rivaroxaban with food to enhance absorption.
• Do not discontinue the medication without consulting a healthcare provider.
• Report any signs of bleeding (e.g., unusual bruising, blood in urine or stool) immediately.
• Inform healthcare providers about rivaroxaban use before any surgical or dental procedures.